Endocrine complications of topical and intralesional corticosteroid therapy.

Curtis, J.; Cormode, Edward J.; Laski, Bernard; Toole, John; Howard, N. J.

doi:10.1136/adc.57.3.204

Cited by 37 publications

(14 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Intralesional and intramuscular GS injections are known to have a prolonged effect on HPA axis suppression. [35][36][37] Interestingly, 2 of the 4 patients in the present study who received intralesional steroid injections had morning cortisol values lower than 1 µg/dL. These were the only undetectable values in the entire study.…”

Section: Hpa Suppressionmentioning

confidence: 74%

Adverse Effects of Systemic Glucocorticosteroid Therapy in Infants With Hemangiomas

George¹,

Sharma²,

Jacobson³

et al. 2004

Arch Dermatol

130

View full text Add to dashboard Cite

To evaluate the short-and long-term adverse effects of systemic glucocorticosteroid (GS) therapy in infants with hemangiomas.Design: Retrospective chart review of infants treated with GSs for hemangiomas during a 3-year period.Setting: Tertiary care children's hospital Patients: Of 141 patients identified with hemangiomas, 22 were treated with GSs.Interventions: Minimum of 1-month GS therapy at a minimum starting dose of 0.5 mg/kg per day.Outcome Measures: Demographic and anthropometric measurements, starting dose and duration of GS therapy, subjective parental concerns, complications related to hemangioma, adjunctive treatment, and morning cortisol levels and/or results of corticotropin stimulation tests. Results:The average starting dose was 2.23 mg/kg per day; average length of therapy was 28.1 weeks. Complaints of irritability, fussiness, or insomnia were identified in 16 patients (73%). Hypertension, defined as 3 or more episodes of systolic blood pressure higher than 105 mm Hg, was observed in 10 patients (45%). Morning cortisol levels were abnormal in 13 (87%) of the 15 patients evaluated. Low-dose corticotropin stimulation test results were abnormal in 2 of the 3 infants tested.Conclusions: While GS therapy for infantile hemangiomas was tolerated well overall, changes in behavior, insomnia, and gastrointestinal symptoms were common parental concerns. Hypertension and hypothalamicpituitary-adrenal axis suppression were observed frequently. Infants undergoing long-term GS treatment of hemangiomas should be monitored carefully for these potential adverse effects.

show abstract

Section: Hpa Suppressionmentioning

confidence: 74%

Adverse Effects of Systemic Glucocorticosteroid Therapy in Infants With Hemangiomas

George¹,

Sharma²,

Jacobson³

et al. 2004

Arch Dermatol

130

View full text Add to dashboard Cite

show abstract

“…The patient resumed a normal growth at the end of the treatment but never returned to his previous percentile. Endocrine complications have also been reported in another study of four patients with non‐esophageal ISI, confirming that ISI leads to a slow and complete absorption of the medication . This is in contradiction with the previous belief that the medication has a high local concentration without any systemic effect.…”

Section: Intralesional Steroid Injectionsmentioning

confidence: 77%

Refractory strictures post-esophageal atresia repair: what are the alternatives?

2013

View full text Add to dashboard Cite

Esophageal strictures remain the most frequent complication after esophageal atresia (EA) repair despite refinements in operative techniques. With an incidence of anastomotic stricture between 8% and 49%, EA is the most frequent cause of benign esophageal stricture in children. The mainstay of treatment for esophageal stricture is dilatation with a 58-96% success rate. In order to relieve dysphagia, between 1 and 15 dilatations will be required in each EA patient with an esophageal stricture. However dilatations may lead to complications including perforation (0.1-0.4% of all esophageal benign strictures) and sociopsychological morbidity. Fifty percent of EA strictures will improve in 6 months. However, 30% will persist and require repeat dilatations. The present article explores the variety of non-surgical alternative treatments for anastomotic strictures after EA repair, focusing on triamcinolone acetonide, mitomycin C and esophageal stents. We propose an algorithm for a more standardized therapeutic approach, with the hope that an international panel of experts could meet and establish a consensus.

show abstract

“…For example, the development of Cushing syndrome has been reported in an infant receiving extensive topical hydrocortisone 0.25% therapy (14). Symptoms of Cushing syndrome also developed in infant,s initially treated unsuccessfully with topical hydrocortisone 0.5%; followed by treatment with topical betamethasone-17valerate cream (15). Not surprisingly, higher potency topical corticosteroids have also been linked to the development of Cushingoid symptoms in infants (16,17).…”

Section: Discussionmentioning

confidence: 99%

Use of an Emollient As a Steroid‐Sparing Agent in the Treatment of Mild to Moderate Atopic Dermatitis in Children

Lucky¹,

Leach

Laskarzewski

et al. 1997

Pediatric Dermatology

147

View full text Add to dashboard Cite

The effectiveness of an emollient as an adjunct to topical corticosteroid therapy for the treatment of mild to moderate atopic dermatitis was studied for 3 weeks in 25 children 3 to 15 years of age in comparison with corticosteroid therapy alone. The adjunctive regimen of a once-daily application each of hydrocortisone 2.5% cream and of a water-in-oil cream was equivalent in efficacy to the comparative regimen of twice-daily applications of hydrocortisone 2.5% cream. Both treatment regimens elicited significant improvement in skin condition by day 7 ( p < 0.005) and further significant improvement by day 14 (p < 0.005). No significant differences between the two treatment regimens were observed in the rates of improvement (p > 0.545) or in the reductions in mean lesion size (p > 0.98). No differences were observed in parental evaluations, except for ease of application where a slight preference was expressed for the hydrocortisone 2.5% cream preparation (p < 0.038). We conclude that emollient adjunctive therapy offers a steroid-sparing alternative to topical corticosteroids alone in the treatment of mild to moderate atopic dermatitis.

show abstract

Endocrine complications of topical and intralesional corticosteroid therapy.

Cited by 37 publications

References 12 publications

Adverse Effects of Systemic Glucocorticosteroid Therapy in Infants With Hemangiomas

Adverse Effects of Systemic Glucocorticosteroid Therapy in Infants With Hemangiomas

Refractory strictures post-esophageal atresia repair: what are the alternatives?

Use of an Emollient As a Steroid‐Sparing Agent in the Treatment of Mild to Moderate Atopic Dermatitis in Children

Contact Info

Product

Resources

About